A new analysis of reviews and articles about the controversial diabetes drug Avandia has found substantial unfounded and unsupported bias in the testifying medical experts who were hired by GlaxoSmithKline, the makers of Avandia, to analyze and discuss the drug's safety and efficacy. Often, medical expert witnesses with favorable opinions about the drug were paid not only by GlaxoSmithKline, but also by its competitors. Of those who offered favorable views, 87% had potential conflicts with Glaxo. Among those who had unfavorable opinions about the drug, only 20% had received money from Glaxo.
Click here to read the entire NY Times article.
